Global intravenous immunoglobulin (IVIG) market is expected to register remarkable growth in the coming years owing to the growing prevalence of chronic inflammatory & primary immunodeficiency diseases and awareness related to therapeutics alternatives. In addition, presence of high unmet needs pertaining to efficient, safe, and technologically advanced treatment techniques are expected fuel the growth of IVIG market over the forecast period.
Moreover, rising adoption of immunoglobulin & albumins in the treatment of chronic diseases, and increasing penetration in bleeding disorders & immune system disorders treatment are the factors attributing towards market growth. IVIG being a major component of the plasma product is used to maintain appropriate level of antibodies in patients with immunodeficiency disorders.
Access full research report:
In addition, emerging concept of hyper-immune globulin for treatment of tetanus, hepatitis B, and rabies and increased efficacy of IVIG treatments that provide passive immunity to patients are the factors anticipated to provide lucrative growth to intravenous immunoglobulin market over the forecast period. Furthermore, introduction of advanced sorbitol-based formulations as an alternative to sucrose-based formulations is expected to increase penetration of these products in the near future.
The intravenous immunoglobulin market is segmented on the basis of type and application. On the basis of type, it is further bifurcated into IgG, IgA, IgM, IgE, and IgD. The intravenous immunoglobulin has clinical applications in nephrology, hematology, neurology, immunology, dermatology, and rheumatology.
Request for TOC of this research report:
Similarly on the basis of therapeutic applications, the market is further segmented into immune deficiencies, acute infections, and autoimmune diseases. The immune deficiency application held one of the largest market share in 2014 owing to its wide therapeutic applications in diseases such as X-linked agammaglobulinemia, acquired compromised immunity conditions (secondary immune deficiencies), and chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia (primary immune deficiencies). Moreover, primary immune deficiencies sub-segment is expected to gain penetration due to unavailability of effective alternatives for IVIG treatment and a large patient population.
Geographically, the industry is segmented into North America, Europe, Asia pacific, Latin America, and MEA. As of 2014, North America held the highest share due to rising prevalence of primary immunodeficiency disorders, technologically advanced treatment options, and favorable government policies in this region. European countries are expected to register positive growth over the coming seven years due to awareness among patients and rising population base with neurological disorders.
Browse more reports of this category by Grand View Research:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information, visit http://www.grandviewresearch.com/
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
Country: United States